Care must be exerted while recommending most commonly prescribed anti-diabetic drugs such as biguanides, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, and insulin as recent reports have observed that these drugs might exacerbate clinical conditions in COVID-19 cases. This evidence concerns the gene INS and COVID-19.